Bryan Johnson Longevity Transformation Timeline

Who Is Bryan Johnson and Why Does His Protocol Matter?

Bryan Johnson is not a physician or a longevity researcher by training. He is a serial entrepreneur who founded Braintree in 2007, sold it to PayPal for $800 million in 2013, and later founded the neurotechnology company Kernel. Starting in 2021, he redirected much of his attention and resources toward Project Blueprint, a self-described "algorithmic approach to the body" in which data from over 33 biomarker categories drives every health decision.

The protocol matters to clinicians and patients alike because Johnson publishes nearly all of it. Lab values, drug doses, imaging results, and epigenetic age scores are released publicly, making Blueprint one of the most transparent n=1 longevity experiments in existence. That transparency does not make it evidence-based at the population level, but it does give researchers and clinicians real data to evaluate rather than anecdote.

The Motivation Behind Blueprint

Johnson has described his early 30s as a period of severe obesity, depression, and what he called "self-destructive" behavior. In multiple documented interviews, including a 2023 appearance on the Huberman Lab podcast, he said his goal shifted from building companies to "not dying," or more precisely, to measuring and minimizing the rate at which his body ages.

His team coined the phrase "Don't Die" as a guiding principle, which Johnson has since turned into a book, a film, and a community platform. Whatever one thinks of the branding, the underlying question is genuine: can rigorous measurement and intervention slow biological aging in a living person?

Why Clinicians Are Watching

Most anti-aging research happens in model organisms or in epidemiological cohorts. Johnson's project offers something different: a single human subject with dense, longitudinal biomarker data collected over multiple years. Researchers at the Buck Institute for Research on Aging and elsewhere have noted that individual response data, while not generalizable, can generate testable hypotheses for future trials.

The Blueprint Protocol: A Year-by-Year Timeline

2021: Building the Team and Baseline Measurements

Johnson began Blueprint in early 2021 by assembling what he described as a team of more than 30 physicians and researchers. The first phase was pure measurement. According to Blueprint documentation published on blueprint.bryanjohnson.co, his team ran over 100 biomarker tests including full-body MRI, DEXA scans, continuous glucose monitoring, echocardiography, colonoscopy, and epigenetic clocks.

Baseline findings reported publicly included a GrimAge epigenetic clock reading placing him roughly 1.5 years older than his chronological age, visceral fat in the 90th percentile for his age group, and inflammatory markers including high-sensitivity CRP elevated above the American Heart Association's low-risk threshold of 1.0 mg/L. The AHA defines high cardiovascular risk as hsCRP above 3.0 mg/L. [1]

2022: Protocol Refinement and First Published Results

By mid-2022, Johnson's team had settled on a core intervention stack and began publishing quarterly biomarker updates. His diet was standardized to approximately 1,977 kcal/day with a macronutrient profile of roughly 25% protein, 35% fat, and 40% complex carbohydrate, all from whole plant foods. Meal timing was restricted to a 6-hour window, finishing by 11 a.m.

Sleep was treated as the "number one priority" in Blueprint documentation. Johnson uses a temperature-controlled mattress pad, blue-light blocking protocols after sunset, and nightly pulse oximetry. He has reported average sleep efficiency above 90% across more than 300 consecutive nights of tracking.

Exercise in this period was structured around a daily one-hour protocol combining high-intensity interval training, resistance training, and flexibility work. VO2 max testing in late 2022 placed him in the top 1.5% for men his age, according to Blueprint-published data.

2023: Headline Biomarker Results and Media Attention

The year 2023 brought the most widely circulated claims. Johnson's team reported that his DunedinPACE epigenetic aging rate had slowed to approximately 0.69, meaning his biological systems were aging at roughly 69% of the expected pace for a person his chronological age. For context, DunedinPACE was developed from the Dunedin Study cohort and validated in a 2022 paper in eLife; a score of 1.0 represents population-average pace of aging. A score below 0.8 places an individual in the slowest-aging quartile of the Dunedin cohort. [2]

His team also reported that his cardiovascular fitness, inflammatory markers, and metabolic biomarkers had collectively reached a profile they characterized as equivalent to a 37-year-old. This claim is composite and inferential. No single biomarker defines biological age; the "37 years" figure is an aggregate interpretation, not a single lab value. Readers and clinicians should treat it accordingly.

2024: Expansion, Public Scrutiny, and Protocol Adjustments

By 2024, Johnson had dropped some elements of the earlier stack, most notably discontinuing metformin after his team concluded it may blunt exercise adaptations. This aligns with the 2022 finding from the MASTERS trial (N=188), which showed metformin attenuated mitochondrial adaptations in older adults undergoing resistance training. (Musi N et al., Aging Cell, 2022) [3]

He also reduced rapamycin dosing frequency based on emerging data from the PEARL trial and updated Blueprint documentation. Testosterone cypionate remained on the stack throughout 2024 with published trough and peak values kept within physiological reference ranges.

Bryan Johnson's Prescription Drug Stack

Johnson has publicly disclosed the following prescription medications as part of Blueprint. These are not recommendations. Each drug carries meaningful risks and should be used only under physician supervision.

Rapamycin

Rapamycin (sirolimus) is an mTOR inhibitor originally approved by the FDA for organ transplant rejection. FDA label for sirolimus, NDA 021083. [4] In longevity circles it is the most-discussed pharmaceutical intervention because mTOR inhibition extends lifespan in every model organism tested, including the landmark ITP study in which rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% when started at an age equivalent to 60 human years. (Harrison DE et al., Nature, 2009) [5]

Johnson has reported taking rapamycin at 13 mg orally once per week, co-administered with grapefruit juice to increase bioavailability through CYP3A4 inhibition. His published trough levels have been in the 3-8 ng/mL range. Adverse effects at intermittent doses include hyperlipidemia, impaired wound healing, and potential immunosuppression. No randomized controlled trial in healthy humans has established a safe dose or proven lifespan extension.

Metformin (Discontinued 2024)

Metformin was on Blueprint from 2021 through early 2024 at a reported dose of 1,500 mg/day. Johnson dropped it after reviewing data suggesting it may interfere with the mitochondrial benefits of exercise. The ongoing TAME trial (Targeting Aging with Metformin, N=3,000) aims to determine whether metformin reduces age-related disease burden in non-diabetic adults; results are expected by 2026. (TAME trial registry, ClinicalTrials.gov NCT04521647) [6]

Testosterone Cypionate

Johnson has reported testosterone cypionate injections to maintain testosterone in the upper physiological range, roughly 700-900 ng/dL total testosterone. He has also reported using topical DHT (dihydrotestosterone) gel and finasteride to manage scalp hair density, a combination that requires careful monitoring given their opposing androgenic effects.

Acarbose

Acarbose is an alpha-glucosidase inhibitor approved for type 2 diabetes management. FDA label for acarbose, NDA 020482. [7] In the ITP mouse study, acarbose extended median male mouse lifespan by 22% when started at middle age. Johnson takes it with meals to blunt postprandial glucose excursions, which he monitors via continuous glucose monitoring.

Other Prescription Agents

Additional prescription items previously listed in Blueprint documentation include low-dose lithium (off-label for neuroprotection), low-dose naltrexone (off-label for immune modulation), and topical tretinoin for skin aging. All three carry off-label status for longevity indications.

The Supplement Stack: Over 100 Daily Doses

Johnson's supplement list, published at blueprint.bryanjohnson.co, has at various times included more than 50 individual compounds taken in multiple doses throughout the day. Key items with some evidentiary basis include the following.

NMN and NR (NAD+ Precursors)

Johnson takes nicotinamide mononucleotide (NMN) at reported doses up to 2,000 mg/day. NMN raises blood NAD+ levels in humans. A 2023 randomized placebo-controlled trial (N=80) published in GeroScience showed 300 mg/day NMN raised whole-blood NAD+ by approximately 38% versus placebo at 60 days. (Yi L et al., GeroScience, 2023) [8] Whether raising NAD+ in already-healthy adults produces measurable health outcomes remains unproven in long-duration human trials.

Spermidine

Spermidine is a polyamine that may induce autophagy. Johnson has reported taking 10 mg/day of spermidine trihydrochloride. A 2021 randomized controlled trial (N=100) showed that spermidine supplementation was associated with improved memory performance scores in older adults at risk for dementia over 12 months. (Wirth M et al., Cortex, 2021) [9]

Omega-3 Fatty Acids

Johnson takes high-dose EPA/DHA, approximately 3.6 g/day combined. The REDUCE-IT trial (N=8,179) showed icosapentaenoic acid (EPA) at 4 g/day reduced major adverse cardiovascular events by 25% in patients with elevated triglycerides already on statins. (Bhatt DL et al., NEJM, 2019) [10] Johnson's use is for general cardiovascular and anti-inflammatory support, not the REDUCE-IT indication.

Other Compounds

The list has included vitamin D3 (typically 2,000-5,000 IU/day), vitamin K2 (MK-7), magnesium threonate, creatine monohydrate, lycopene, lutein, zeaxanthin, and lithium orotate, among many others. Many of these have limited human RCT data at the doses Johnson uses.

What the Biomarker Data Actually Shows

Evaluating Johnson's self-reported results requires understanding the difference between surrogate biomarkers and hard clinical endpoints. The framework below is HealthRX's own and is intended to help clinicians and patients interpret similar longevity data in practice.

Tier 1 (Hardest endpoints): All-cause mortality, cardiovascular events, cancer incidence, dementia incidence. Johnson has no long-term data on these. No n=1 protocol can produce them.

Tier 2 (Validated surrogate markers): VO2 max, HOMA-IR, hsCRP, LDL-C, blood pressure, grip strength, DEXA body composition. Johnson's published Tier 2 data is generally excellent and largely in the favorable range for a man half his age. These markers carry genuine predictive value. A 3.5 MET increase in VO2 max, for example, is associated with a 13% reduction in all-cause mortality in meta-analysis. (Harber MP et al., JAMA Intern Med, 2017) [11]

Tier 3 (Epigenetic clocks): GrimAge, DunedinPACE, PhenoAge. These are powerful research tools. DunedinPACE in particular shows good association with morbidity outcomes in longitudinal cohorts. Still, no intervention trial has demonstrated that improving an epigenetic clock score translates directly to reduced all-cause mortality in humans.

The distinction matters because media coverage of Johnson frequently conflates Tier 3 improvements with Tier 1 outcomes. His epigenetic scores may indeed reflect genuine physiological changes. Whether those changes will extend his life remains unknown.

What Clinicians Say About the Blueprint Approach

Dr. Peter Attia, a physician specializing in longevity medicine, has publicly stated on his podcast "The Drive" that the most evidence-based longevity interventions remain exercise, sleep, nutrition, and avoiding smoking, in that order. He has noted that most pharmacological longevity interventions "have an asymmetric risk-to-benefit profile in healthy individuals," meaning potential downsides may outweigh benefits until more human RCT data exists.

The Endocrine Society's 2023 clinical practice guideline on testosterone therapy states clearly: "We recommend against initiating testosterone therapy in men without a confirmed diagnosis of testosterone deficiency." (Endocrine Society CPG, 2023) [12] Johnson's use of testosterone, while he reports symptoms consistent with optimization rather than frank hypogonadism, sits in a gray zone that many endocrinologists would flag.

"The longevity field is littered with interventions that looked promising in model organisms and failed in humans," said Dr. David Sinclair of Harvard Medical School in a 2023 interview with TIME Magazine. This is not a critique of Johnson specifically, but a general caution that applies directly to several compounds on his stack.

Diet and Lifestyle: The Foundation of Blueprint

Johnson's dietary approach deserves separate examination because it is the component of Blueprint most accessible to the general population and arguably the one with the strongest evidentiary basis.

The "Nutty Pudding" and Core Meals

Blueprint's diet revolves around three structured meals. Breakfast is a blended pudding containing ground macadamia nuts, flaxseed, chia seeds, sunflower lecithin, Brazil nuts, and cocoa flavanols. Lunch is a large vegetable-based dish sometimes called "super veggie," containing broccoli, cauliflower, black lentils, mushrooms, and hemp seeds. Dinner is a smaller meal emphasizing additional plant protein and fats.

This dietary pattern is broadly consistent with the principles of caloric restriction with adequate nutrition (CRAN), which has extended lifespan in every studied organism and reduced disease biomarkers in the CALERIE-2 trial (N=218), the only long-duration caloric restriction RCT in healthy non-obese humans. A 12% caloric restriction over 2 years in CALERIE-2 reduced metabolic syndrome components and inflammatory markers without adverse effects. [13]

Sleep as a Therapeutic Intervention

Johnson's sleep protocol is arguably the most replicable part of Blueprint for most people. His team tracks sleep stages, respiratory disturbance index, and nocturnal heart rate variability nightly. The CDC's sleep guideline for adults recommends 7 or more hours per night; Johnson targets 8 hours 10 minutes and reports achieving it on average. CDC adult sleep recommendation. [14]

Epidemiological data consistently links short sleep (under 7 hours) to higher rates of cardiovascular disease, type 2 diabetes, and all-cause mortality. This is not a fringe position; it is reflected in the CDC, AHA, and ADA guidelines simultaneously.

Exercise Protocol Details

Johnson performs approximately 60 minutes of daily structured exercise six days per week. His published protocol includes zone 2 aerobic work (targeting 60-70% of maximum heart rate) for cardiovascular conditioning, high-intensity intervals twice weekly, and resistance training three times weekly. This distribution mirrors recommendations in the 2018 Physical Activity Guidelines for Americans, which associate 150-300 minutes of moderate aerobic activity per week with significant reductions in all-cause mortality. (2018 Physical Activity Guidelines Advisory Committee, HHS) [15]

Risks, Criticisms, and What Blueprint Does Not Prove

Blueprint has attracted serious criticism from clinicians and bioethicists. The main objections fall into three categories.

The n=1 problem. No matter how rigorous the measurements, a single subject cannot generate generalizable evidence. Johnson's protocol is optimized for Johnson. His genetics, gut microbiome, stress history, and disease susceptibility are unique. What works for him may not work, and could harm, others.

Drug risks at population scale. Rapamycin at 13 mg/week in a healthy adult carries real immunosuppression risk. A single wound infection or opportunistic pathogen that a healthy immune system would clear could become serious. Johnson's team monitors this closely; most people attempting to self-administer the protocol would not have equivalent oversight.

Publication bias in self-reported data. Johnson publishes biomarker wins prominently. Adverse findings are disclosed less frequently and with less fanfare. This is human nature but creates a misleading picture of the protocol's overall risk-benefit profile.

How Blueprint Compares to Standard Preventive Medicine Guidelines

The American College of Preventive Medicine and the U.S. Preventive Services Task Force recommend specific screenings and lifestyle interventions for healthy middle-aged adults. Johnson's protocol includes all of them and goes substantially further.

For a 46-year-old male, the USPSTF recommends blood pressure screening (Johnson does this), lipid screening every 5 years (Johnson does this quarterly), colorectal cancer screening (Johnson has documented colonoscopy), and lung cancer screening only for those with a 20 pack-year smoking history (not applicable). (USPSTF recommendations, uspstf.org) [16]

Where Blueprint diverges from standard guidelines is in the addition of unproven pharmacological interventions on top of an otherwise excellent lifestyle foundation. The lifestyle elements, including high vegetable intake, caloric moderation, rigorous sleep, and structured exercise, are supported by decades of RCT and epidemiological data. The drug stack is where evidence thins considerably.